ASX - By Stock
|
NEU |
Re:
Neuren Media and Analyst Coverage
|
|
Taurean7
|
1.3K |
696K |
30 |
18/08/24 |
18/08/24 |
ASX - By Stock
|
1.3K
|
696K
|
30
|
|
ASX - By Stock
|
NEU |
Re:
Neuren Media and Analyst Coverage
|
|
Taurean7
|
1.3K |
696K |
15 |
17/08/24 |
17/08/24 |
ASX - By Stock
|
1.3K
|
696K
|
15
|
|
ASX - By Stock
|
NEU |
Re:
Neuren Media and Analyst Coverage
|
|
Taurean7
|
1.3K |
696K |
3 |
17/08/24 |
17/08/24 |
ASX - By Stock
|
1.3K
|
696K
|
3
|
|
ASX - By Stock
|
NEU |
Re:
Neuren Media and Analyst Coverage
|
|
Taurean7
|
1.3K |
696K |
17 |
17/08/24 |
17/08/24 |
ASX - By Stock
|
1.3K
|
696K
|
17
|
|
ASX - By Stock
|
NEU |
Re:
Neuren Media and Analyst Coverage
|
|
Taurean7
|
1.3K |
696K |
10 |
17/08/24 |
17/08/24 |
ASX - By Stock
|
1.3K
|
696K
|
10
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
Taurean7
|
11K |
5.3M |
23 |
14/08/24 |
14/08/24 |
ASX - By Stock
|
11K
|
5.3M
|
23
|
|
ASX - By Stock
|
DXB Medicine |
Re:
DXB Media thread.
|
|
Taurean7
|
210 |
114K |
40 |
14/08/24 |
14/08/24 |
ASX - By Stock
|
210
|
114K
|
40
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
Taurean7
|
11K |
5.3M |
49 |
14/08/24 |
14/08/24 |
ASX - By Stock
|
11K
|
5.3M
|
49
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Phase 2 trial shows significant improvements in Angelman
|
|
Taurean7
|
87 |
44K |
78 |
09/08/24 |
09/08/24 |
ASX - By Stock
|
87
|
44K
|
78
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Trading Halt
|
|
Taurean7
|
76 |
40K |
5 |
07/08/24 |
07/08/24 |
ASX - By Stock
|
76
|
40K
|
5
|
|
ASX - By Stock
|
TLX |
Re:
Ann: Investor Conference Call - TLX250-CDx BLA Filing Update
|
|
Taurean7
|
19 |
9.9K |
17 |
06/08/24 |
06/08/24 |
ASX - By Stock
|
19
|
9.9K
|
17
|
|
ASX - By Stock
|
NEU |
Re:
Neuren Media and Analyst Coverage
|
|
Taurean7
|
1.3K |
696K |
8 |
02/07/24 |
02/07/24 |
ASX - By Stock
|
1.3K
|
696K
|
8
|
|
ASX - By Stock
|
DXB |
Re:
DXB Chart
|
|
Taurean7
|
1.3K |
538K |
15 |
30/06/24 |
30/06/24 |
ASX - By Stock
|
1.3K
|
538K
|
15
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Phase I/II UTI/Urosepsis Rapid Infusion Trial Complete
|
|
Taurean7
|
72 |
19K |
16 |
30/06/24 |
30/06/24 |
ASX - By Stock
|
72
|
19K
|
16
|
|
ASX - By Stock
|
NEU |
Re:
Neuren Media and Analyst Coverage
|
|
Taurean7
|
1.3K |
696K |
27 |
28/06/24 |
28/06/24 |
ASX - By Stock
|
1.3K
|
696K
|
27
|
|
ASX - By Stock
|
SLX Energy |
Re:
Nuclear Power Related Media Thread
|
|
Taurean7
|
5.3K |
2.2M |
6 |
24/06/24 |
24/06/24 |
ASX - By Stock
|
5.3K
|
2.2M
|
6
|
|
ASX - By Stock
|
TLX |
Re:
Short Term trading, analysis and TLX noise - No investors keep out
|
|
Taurean7
|
632 |
229K |
16 |
23/06/24 |
23/06/24 |
ASX - By Stock
|
632
|
229K
|
16
|
|
ASX - By Stock
|
TLX |
Re:
News: TLX Telix Pharmaceuticals Aims Up To $4.17 Bln Valuation In US IPO
|
|
Taurean7
|
112 |
45K |
7 |
06/06/24 |
06/06/24 |
ASX - By Stock
|
112
|
45K
|
7
|
|
Humour
|
|
Re:
Mowing lawns
|
|
Taurean7
|
17 |
3.8K |
3 |
02/06/24 |
02/06/24 |
Humour
|
17
|
3.8K
|
3
|
|
ASX - By Stock
|
CU6 |
Re:
Research/Valuation
|
|
Taurean7
|
636 |
227K |
9 |
26/05/24 |
26/05/24 |
ASX - By Stock
|
636
|
227K
|
9
|
|
Charts
|
NEU |
Re:
NEU chart
|
|
Taurean7
|
1.8K |
971K |
11 |
15/05/24 |
15/05/24 |
Charts
|
1.8K
|
971K
|
11
|
|
Charts
|
NEU |
Re:
NEU chart
|
|
Taurean7
|
1.8K |
971K |
12 |
15/05/24 |
15/05/24 |
Charts
|
1.8K
|
971K
|
12
|
|
Charts
|
NEU |
Re:
NEU chart
|
|
Taurean7
|
1.8K |
971K |
21 |
15/05/24 |
15/05/24 |
Charts
|
1.8K
|
971K
|
21
|
|
Charts
|
NEU |
Re:
NEU chart
|
|
Taurean7
|
1.8K |
971K |
20 |
15/05/24 |
15/05/24 |
Charts
|
1.8K
|
971K
|
20
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: Complete response with Cu-67 SAR-bisPSMA
|
|
Taurean7
|
73 |
24K |
13 |
04/05/24 |
04/05/24 |
ASX - By Stock
|
73
|
24K
|
13
|
|
ASX - By Stock
|
NEU |
Re:
Ann: 2023 Annual Report to shareholders
|
|
Taurean7
|
194 |
81K |
15 |
29/04/24 |
29/04/24 |
ASX - By Stock
|
194
|
81K
|
15
|
|
ASX - By Stock
|
TLX |
Re:
TLX Chart
|
|
Taurean7
|
1.5K |
601K |
7 |
28/04/24 |
28/04/24 |
ASX - By Stock
|
1.5K
|
601K
|
7
|
|
Charts
|
XRF |
Re:
XRF Charts
|
|
Taurean7
|
78 |
35K |
5 |
28/04/24 |
28/04/24 |
Charts
|
78
|
35K
|
5
|
|
ASX - By Stock
|
NEU |
Re:
Ann: 2023 Annual Report to shareholders
|
|
Taurean7
|
194 |
81K |
37 |
25/04/24 |
25/04/24 |
ASX - By Stock
|
194
|
81K
|
37
|
|
ASX - By Stock
|
TLX |
Re:
TLX Chart
|
|
Taurean7
|
1.5K |
601K |
8 |
24/04/24 |
24/04/24 |
ASX - By Stock
|
1.5K
|
601K
|
8
|
|
ASX - By Stock
|
A4N |
Re:
A4N versus QPM and CCM
|
|
Taurean7
|
19 |
8.8K |
7 |
21/04/24 |
21/04/24 |
ASX - By Stock
|
19
|
8.8K
|
7
|
|
ASX - By Stock
|
A4N |
Re:
Ann: Projects Update
|
|
Taurean7
|
74 |
26K |
16 |
17/04/24 |
17/04/24 |
ASX - By Stock
|
74
|
26K
|
16
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Pharmaceuticals - Business Update
|
|
Taurean7
|
22 |
9.1K |
12 |
10/04/24 |
10/04/24 |
ASX - By Stock
|
22
|
9.1K
|
12
|
|
ASX - By Stock
|
DRO |
Re:
DRO - Chart and TA.
|
|
Taurean7
|
1.6K |
667K |
4 |
22/03/24 |
22/03/24 |
ASX - By Stock
|
1.6K
|
667K
|
4
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Next Cohort Dosing Ph I/II UTI/Urosepsis Clinical Trial
|
|
Taurean7
|
39 |
9.5K |
6 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
39
|
9.5K
|
6
|
|
ASX - By Stock
|
DRO |
Re:
Ann: Change of Director's Interest Notice
|
|
Taurean7
|
183 |
58K |
20 |
07/03/24 |
07/03/24 |
ASX - By Stock
|
183
|
58K
|
20
|
|
ASX - By Stock
|
NEU |
Re:
Ann: 2023 Results webinar
|
|
Taurean7
|
130 |
65K |
44 |
02/03/24 |
02/03/24 |
ASX - By Stock
|
130
|
65K
|
44
|
|
ASX - By Stock
|
DUG |
Re:
Share Price Discussion
|
|
Taurean7
|
89 |
42K |
3 |
26/02/24 |
26/02/24 |
ASX - By Stock
|
89
|
42K
|
3
|
|
ASX - By Stock
|
SLX |
Re:
Chart
|
|
Taurean7
|
372 |
122K |
16 |
17/02/24 |
17/02/24 |
ASX - By Stock
|
372
|
122K
|
16
|
|
Charts
|
NEU |
Re:
NEU chart
|
|
Taurean7
|
1.8K |
971K |
25 |
17/02/24 |
17/02/24 |
Charts
|
1.8K
|
971K
|
25
|
|
ASX - By Stock
|
CU6 |
Re:
Research/Valuation
|
|
Taurean7
|
636 |
227K |
28 |
10/02/24 |
10/02/24 |
ASX - By Stock
|
636
|
227K
|
28
|
|
ASX - By Stock
|
TLX Biotech |
Re:
Nuclear Medicine: From Concept to Clinic and Commercialization (CB chapter in Pr. Richard Baum tribute book)
|
|
Taurean7
|
17 |
8.8K |
5 |
12/01/24 |
12/01/24 |
ASX - By Stock
|
17
|
8.8K
|
5
|
|
ASX - By Stock
|
NEU |
Re:
Forecasts 2024
|
|
Taurean7
|
40 |
20K |
20 |
03/01/24 |
03/01/24 |
ASX - By Stock
|
40
|
20K
|
20
|
|
ASX - By Stock
|
NEU |
Re:
Forecasts 2024
|
|
Taurean7
|
40 |
20K |
31 |
03/01/24 |
03/01/24 |
ASX - By Stock
|
40
|
20K
|
31
|
|
ASX - By Stock
|
TLX |
Re:
TLX Chart
|
|
Taurean7
|
1.5K |
601K |
27 |
31/12/23 |
31/12/23 |
ASX - By Stock
|
1.5K
|
601K
|
27
|
|
ASX - By Stock
|
NEU |
Re:
Forecasts 2024
|
|
Taurean7
|
40 |
20K |
11 |
26/12/23 |
26/12/23 |
ASX - By Stock
|
40
|
20K
|
11
|
|
ASX - By Stock
|
NEU |
Re:
Forecasts 2024
|
|
Taurean7
|
40 |
20K |
7 |
26/12/23 |
26/12/23 |
ASX - By Stock
|
40
|
20K
|
7
|
|
ASX - By Stock
|
NEU |
Re:
Forecasts 2024
|
|
Taurean7
|
40 |
20K |
7 |
26/12/23 |
26/12/23 |
ASX - By Stock
|
40
|
20K
|
7
|
|
ASX - By Stock
|
RCE |
Re:
Ann: RCE Awarded $43.7m AusIndustry Advanced Overseas Finding
|
|
Taurean7
|
32 |
11K |
20 |
14/12/23 |
14/12/23 |
ASX - By Stock
|
32
|
11K
|
20
|
|
Charts
|
NEU |
Re:
NEU chart
|
|
Taurean7
|
1.8K |
971K |
32 |
20/11/23 |
20/11/23 |
Charts
|
1.8K
|
971K
|
32
|
|